Screener
Inhibrx Biosciences, Inc. INBX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $25,217 | $36,877 |
| General and administrative | 5,710 | 6,024 |
| Total operating expenses | 30,927 | 42,901 |
| Loss from operations | (30,927) | (42,901) |
| Other income (expense): | ||
| Interest expense | (3,509) | (2,689) |
| Interest income | 1,007 | 2,329 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s total operating expenses?
- Inhibrx Biosciences, Inc. (INBX) reported total operating expenses of $30.93M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s total operating expenses changed year-over-year?
- Inhibrx Biosciences, Inc.'s total operating expenses decreased by 27.9% year-over-year, from $42.9M to $30.93M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s total operating expenses?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s total operating expenses has grown at a -21.5% compound annual growth rate (CAGR), from $221.02M to $136.33M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Inhibrx Biosciences, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude